Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk

MLA

Huberta E. Hart, et al. “Evaluation of SGLT-2 Inhibitor Treatment in Type 2 Diabetes Patients with Very High Cardiovascular Risk.” Primary Care Diabetes, vol. 17, Apr. 2023, pp. 190–94. EBSCOhost, https://doi.org/10.1016/j.pcd.2023.02.001.

APA

Huberta E. Hart, Olivier Kievits, Frans H. Rutten, & Monika H. Hollander. (2023). Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk. Primary Care Diabetes, 17, 190–194. https://doi.org/10.1016/j.pcd.2023.02.001

Chicago

Huberta E. Hart, Olivier Kievits, Frans H. Rutten, and Monika H. Hollander. 2023. “Evaluation of SGLT-2 Inhibitor Treatment in Type 2 Diabetes Patients with Very High Cardiovascular Risk.” Primary Care Diabetes 17 (April): 190–94. doi:10.1016/j.pcd.2023.02.001.